Jim Cramer Wants You to Watch Out For These 10 Stocks

6. Medtronic plc (NYSE:MDT)

Number of Hedge Fund Investors: 52

Jim Cramer notes that Medtronic plc (NYSE:MDT) has recently seen several upgrades to its price targets following its earnings report on Tuesday. Baird raised its target from $82 to $90 per share but maintained a hold-equivalent rating, while Wells Fargo (NYSE:WFC) increased its target to $106 and kept an overweight rating.

“Medtronic picked up multiple price target bumps after its earnings report Tuesday. Baird goes to $90 a share from $82 but kept its hold-equivalent rating. Wells Fargo went up a dollar to $106 and maintained its overweight rating. Its neuromodulation business was a standout in the quarter.”

Medtronic plc (NYSE:MDT) is a major player in the medical device field, with a wide range of products across cardiovascular, diabetes, and neurological areas. Its large market share and global presence set the stage for ongoing growth. Medtronic plc (NYSE:MDT) is dedicated to innovation, shown by its strong lineup of new products and technologies, including advancements in robotic-assisted and minimally invasive surgeries. The introduction of the Hugo™ robotic-assisted surgery system highlights Medtronic’s strategy to stay ahead in the market and boost future revenue.

Recent financial reports show Medtronic plc (NYSE:MDT)’s steady revenue growth, with a 5% increase compared to last year, reflecting strong demand for its products. Medtronic plc (NYSE:MDT)’s focus on cost control and efficiency has improved its profit margins and financial health. As demand for advanced medical technologies rises and the global population ages, Medtronic plc (NYSE:MDT) is well-positioned to benefit from these trends. Recent acquisitions, like Mazor Robotics, have strengthened its capabilities in neurosurgery, which is expected to drive future growth and increase value for shareholders.